All In Biotech

Drug Trial Radar · NCT04498741

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

89

Actual

Start

Jul 8, 2020

Primary completion

May 27, 2021

Study completion Jun 1, 2021

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
Pharmaceutical Research Associates
First posted
Aug 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of tacrolimus, dabigatran, rosuvastatin and midazolam on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

Conditions

  • RSV Infection

Interventions

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)

  • TacrolimusDrug

    Subjects will receive tacrolimus once daily on Day 1 and Day 24

  • DabigatranDrug

    Subjects will receive dabigatran once daily on Day 1 and Day 13

  • RosuvastatinDrug

    Subjects will receive rosuvastatin once daily on Day 1 and Day 13

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)

  • MidazolamDrug

    Subjects will receive midazolam once daily on Day 1 and Day 16

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of tacrolimus with and without coadministration with EDP-938Time frame: up to 29 days
  2. AUC of tacrolimus with and without coadministration with EDP-938Time frame: up to 29 days
  3. Cmax of dabigatran with and without coadministration with EDP-938Time frame: up to 17 days
  4. AUC of dabigatran with and without coadministration with EDP-938Time frame: up to 17 days
  5. Cmax of rosuvastatin with and without coadministration with EDP-938Time frame: up to 17 days
  6. AUC of rosuvastatin with and without coadministration with EDP-938Time frame: up to 17 days
  7. Cmax of midazolam with and without coadministration with EDP-938Time frame: up to 17 days
  8. AUC of midazolam with and without coadministration with EDP-938Time frame: up to 17 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaceutical Research Associates, Inc.,

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.